Nicotinic Acetylcholine Receptors in the Mesolimbic Pathway: Primary Role of Ventral Tegmental Area α6β2* Receptors in Mediating Systemic Nicotine Effects on Dopamine Release, Locomotion, and Reinforcement

• DOI: 10.1523/jneurosci.5095-09.2010
• Publication Date: 2010-04-14T16:40:34Z
• Authors: Cecilia Gotti; Stefania Guiducci; Vincenzo Tedesco; Silvia Corbioli; Lara Zanetti; Milena Moretti; Alessio Zanardi; Roberto Rimondini; Manolo Mugnaini; Francesco Clementi; Christian Chiamulera; Michele Zoli
• Keywords: Male; 0301 basic medicine; Nicotine; Dopamine; Self Administration; Nicotinic Antagonists; Motor Activity; Receptors, Nicotinic; Nucleus Accumbens; Rats, Sprague-Dawley; 03 medical and health sciences; Mesencephalon; Neural Pathways; Animals; Nicotinic Agonists; Neurons; Ventral Tegmental Area; nicotinic receptors ; nicotine ; dopaminergic pathway; Feeding Behavior; Corpus Striatum; Rats; nicotinic acethylcholine receptors; nicotine; nicotinic acetylcholine receptor; mesostriatal dopamine pathway; dopamine release; locomotion; nicotine self-administration; alpha-conotoxin MII.; NICOTINE; DOPAMINE RELEASE; REINFORCEMENT; RECEPTOR; MICRODIALYSIS; Conotoxins; Reinforcement, Psychology

α6* nicotinic acetylcholine receptors (nAChRs) are highly and selectively expressed by mesostriatal dopamine (DA) neurons. These neurons are thought to mediate several behavioral effects of nicotine, including locomotion, habit learning, and reinforcement. Yet the functional role of α6* nAChRs in midbrain DA neurons is mostly unknown. The aim of this study was to determine the composition andin vivofunctional role of α6* nAChR in mesolimbic DA neurons of male rats. Immunoprecipitation and immunopurification techniques coupled with cell-specific lesions showed that the composition of α6* nAChR in the mesostriatal system is heterogeneous, with (non-α4)α6β2* being predominant in the mesolimbic pathway and α4α6β2* in the nigrostriatal pathway. We verified whether α6* receptors mediate the systemic effects of nicotine on the mesolimbic DA pathway by perfusing the selective antagonists α-conotoxin MII (CntxMII) (α3/α6β2* selective) or α-conotoxin PIA (CntxPIA) (α6β2* selective) into ventral tegmental area (VTA). The intra-VTA perfusion of CntxMII or CntxPIA markedly decreased systemic nicotine-elicited DA release in the nucleus accumbens and habituated locomotion; the intra-VTA perfusion of CntxMII also decreased the rate of nicotine infusion in the maintenance phase of nicotine, but not of food, self-administration. Overall, the results of these experiments show that the α6β2* nAChRs expressed in the VTA are necessary for the effects of systemic nicotine on DA neuron activity and DA-dependent behaviors such as locomotion and reinforcement, and suggest that α6β2*-selective compounds capable of crossing the blood–brain barrier may affect the addictive properties of nicotine and therefore be useful in the treatment of tobacco dependence.